According to filings with the U.S. Securities and Exchange Commission, Iambic Therapeutics is raising up to $37,999,999.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Thomas Miller played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Iambic Therapeutics
Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

To learn more about Iambic Therapeutics, visit http://www.iambic.ai/

Contact:
Thomas Miller, Chief Executive Officer
626-592-2520
https://www.linkedin.com/in/thomas-miller-322a8521/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.